sftd
Generic Lamisil® Tablets and OTC Terbinafine Cream, Approved by the FDA
Filed in archive News , Treatment by Gloria Gamat on July 4, 2007
lamisil_250mg_tablets.jpg
A product of Novartis, Lamisil® (terbinafine hydrochloride) Tablets is a prescription drug for the treatment of nail fungus infection (onychomycosis).

Now, the FDA has approved the first generic versions of Lamisil® (terbinafine hydrochloride tablets in 250-milligram formulations) from multiple generic drug manufacturers:


  • Amneal Pharmaceuticals

  • Apotex Corporation

  • Aurobindo Pharma USA Inc.

  • Dr. Reddy's Laboratories Ltd.

  • Gedeon Richter USA Inc.

  • Genpharm Inc.

  • Glenmark Pharmaceuticals Inc.

  • InvaGen Pharmaceuticals Inc.

  • Mylan Pharmaceuticals Inc.

  • Orgenus Pharma Inc.

  • Roxane Laboratories Inc.

  • TEVA Pharmaceuticals USA

  • Watson Laboratories Inc.

  • Wockhardt USA Inc.



In addition, the FDA also approved an application for a generic version of over-the-counter (OTC) Lamisil cream (terbinafine hydrochloride, 1 percent) for the treatment of athlete's foot, manufactured by Taro Pharmaceuticals U.S.A.

Source: FDA News


Permalink: Generic Lamisil® Tablets and OTC Terbinafine Cream, Approved by the FDA
Tags: nail  fungus  athletes  foot  Lamisil  tablets  terbinafine  cream  contact  contact+lenses 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/78947
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Generic Lamisil® Tablets and OTC Terbinafine Cream, Approved by the FDA:

  • Currently 8.50/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.50 out of 2 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!